Delivering confidence in drug development

ICDD

Founded in 2007, ICDD-sas is a science-based company, established as a contract research provider and with its activities focused on predictive toxicology. ICDD-sas uses its proprietary secondary screening platforms to select the safest drugs from the most active lead molecules developed and provided by our clients.

ICDD-sas is located close to Aix-en-Provence, France, in a state of the art Euro 2 million facility, covering 1600 square metres that acts as an incubator for emerging companies developing and commercializing innovative technologies.
The scientists at ICDD-sas boast a combined experience of 40 years in drug development, biochemistry, cell biology, neuroscience and immunology, having analyzed more than 100 new chemical entities at different stages of pre-clinical & clinical development.

The Drug Development Need

Drug development costs have increased 4-fold in the last 20 years, while the new treatments reaching the market each year have declined by almost 50%. Drug failure is usually due either to unexpected human toxicity or otherwise because of a lack of efficacy. Toxicity and lack of efficacy are often discovered only late in the costly clinical development program. ICDD-sas, using its proprietary know how, effectively addresses both of these challenges thereby enhancing the development of safer, more effective medicines, whilst reducing late stage development failures, development time and costs.